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Introduction
In a debate to discuss whether LDL cholesterol should be
decreased to very low levels to achieve optimal cardiovas-
cular risk reduction, the viewpoint defending aggressive
intervention is usually considered the most logical stance
and is by far the most popular position. We defend the
opposite viewpoint in this paper; that is, not all high risk
patients should have the objective to reach a low LDL
concentration (defined as any prespecified number sub-
stantially lower than 130 or 100 mg/dl). We will present,
in this brief discussion, the case that the most important
lipid maneuver in high risk patients with inappropriate LDL
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Abstract
The importance of low-density lipoprotein (LDL) control in the management of patients at high risk of
cardiovascular events is unquestionable. The major statin trials have shown that the benefits of LDL
lowering extend throughout the range of risk and the range of serum cholesterol, and have indicated
that the protective effects of the intervention are mostly related to the baseline risk. Statin therapy is, for
this reason, currently seen as an anti-atherogenic approach for the majority of high risk individuals and
possibly all coronary heart disease patients. This debate is not about the value of statin therapy or the
importance of LDL reduction, but about the goals to be set once we decide that LDL cholesterol must
be reduced. With the National Cholesterol Education Program (NCEP) guidelines representing a solid
middle ground, the two viewpoints in this debate try to argue, on one hand, that the LDL goals should
be substantially lower than our current standards or, on the other, that a specific on-treatment LDL
value may not be the most important goal to pursue. We defend the latter position by presenting the
case that the most effective LDL intervention in high risk patients is to achieve a reduction of at least
30%. This strategy complies with the NCEP guidelines, as most of the high risk patients treated with
an average dose of an average statin would experience a 30–40% LDL reduction that would put on-
treatment LDL levels safely below goal. Our position differs from both the guidelines and the
proponents of more aggressive LDL goals in the management of the two extremes of the cholesterol
distribution, where our lack of interest in a predefined on-treatment LDL concentration would make us
more aggressive than guidelines on low baseline LDL patients and less aggressive than guidelines on
high baseline LDL patients.
Keywords: atherosclerosis, clinical trials, coronary disease prevention, coronary heart disease risk, low-density
lipoprotein cholesterol, meta-analyses, statins
Received: 21 December 2000
Revisions requested: 3 January 2001
Revisions received: 4 January 2001
Accepted: 4 January 2001
Published: 30 January 2001
Curr Control Trials Cardiovasc Med 2001, 2:8–11
This article may contain supplementary data which can only be found
online at http://cvm.controlled-trials.com/content/2/1/008
© 2001 BioMed Central Ltd
(Print ISSN 1468-6708; Online 1468-6694)Available online http://cvm.controlled-trials.com/content/2/1/008
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
p
r
i
m
a
r
y
 
r
e
s
e
a
r
c
h
is a significant reduction from baseline (approximately
30–40%), rather than the attainment of a specific on-treat-
ment level. Not only is this approach largely in agreement
with the goals set by the NCEP guidelines [1], as it drives
the majority of high risk patients to a LDL level of less than
130 or 100 mg/dl, but it is even more aggressive than the
guidelines for the high risk patients with low baseline LDL
(130 mg/dl or lower). For the small population of high risk
patients with high baseline LDL (200 mg/dl and higher),
debating on the appropriate lipid goal is a frivolous exer-
cise because the high prevalence of genetic dyslipidemias
in this group attenuates the response to treatment. The
most reasonable position is to accept the results of high
dose lipid-lowering therapy, whether achieved with a
single drug or a combination regimen when necessary.
Among the frequently cited arguments in favor of low
targets for LDL are, first, the fact that coronary heart disease
(CHD) rates correlate with average plasma cholesterol
levels within and between countries, with the lowest rates
shown by people with a total cholesterol lower than
150 mg/dl [2,3]. Second, secondary prevention trials have
shown a direct correlation between degree of LDL lowering
and the extent of angiographic or clinical benefits [4,5].
Finally, the incomplete successes of the statin trials might
have been amplified had larger proportions of study sub-
jects reached their LDL goal. On the contrary, the propo-
nents of a less aggressive approach to LDL management
question the safety of very low LDL levels [6], cite data from
statin trials showing reduced or absent benefits in patients
with baseline low LDL [7] or in any patients after the initial
25% drop in LDL [8–10], and invoke the possibility that the
impressive results obtained with statins are partly due to
direct effects of the drug on the vascular wall and are there-
fore somewhat independent of LDL changes [11].
Before emphasizing the basis for our position, we think it
necessary to state what we do not consider valid argu-
ments against aggressively low LDL goals. First, there is
danger in achieving LDL levels between 50 and 75 mg/dl.
Although LDL is an important vehicle to transport vitamin
A and vitamin E as well as cholesterol to tissues, data from
subjects with the heterozygous form of hypobetalipopro-
teinemia clearly indicate the safety of low LDL [12,13].
Untoward effects of low LDL may become evident for con-
centrations below 25 mg/dl [14], a value that is rarely
reached with statin therapy in common high risk patients.
Second, a small reduction in LDL may be just as good as
a larger one. It is undeniable that, particularly in high risk
patients, LDL reductions to extremely low levels should
decrease the atherogenic pressure more than more mod-
erate interventions would. The difference between benefits
achieved with one approach versus the other may,
however, be too small too justify aggressive interventions,
as clinical trials have indicated that up to 85% of the pre-
ventive effect of lipid lowering is collected after the initial
25% drop in LDL from baseline [15]. Finally, LDL reduc-
tion is not a therapeutic objective at all in some high risk
patients. Although data showing significant clinical bene-
fits in high risk patients with low HDL and low LDL treated
with gemfibrozil are available [16], it is unquestionable that
the mediator of risk in low HDL conditions is the level of
the atherogenic lipoproteins. It is also unquestionable that
LDL and remnant reduction in these patients represent the
best approach to reducing the cholesterol/high-density
lipoprotein (HDL) ratio as well as CHD risk.
LDL lowering and atherosclerosis
To prepare the ground for our argument, we need to revisit
the biology of atherogenesis. Plaque development in the
vessel wall depends always on the accumulation of lipid
material in the subendothelial space, a phenomenon that
directly or indirectly triggers all other aspects of lesion
growth, including macrophage recruitment, foam cell forma-
tion, and the inflammatory response in the artery wall. After
more than 90 years of studies on atherosclerosis, it is clear
that the pathology of the lesion is dependent on cholesterol
accumulation, and that no alternative pathways to the initia-
tion of atherogenesis are in place [17,18]. This means that,
even in subjects whose main CHD risk factors are not
related to lipids, the atherogenic pressures are translated
into a ‘permissive’ environment that allows lipid accumula-
tion in the vessel wall. In other words, a diabetic hyperten-
sive patient with a LDL level of 115 mg/dl and a HDL level
of 34 mg/dl has increased risk because insulin resistance,
hyperglycemia, and high blood pressure affect the endothe-
lium, the intima, and the rest of the vessel wall so that the
environment becomes permissive for lipid deposition, which
initiates the atherosclerotic process. In this scenario, lower-
ing LDL and raising HDL are clinically beneficial because
they affect the plasma and tissue concentration of the ‘initia-
tors’ of atherogenesis even if the ‘permissive’ factors are not
modified. This hypothesis finds support in the data of clinical
trials such as the United Kingdom Prospective Diabetes
Study (UKPDS) [19,20], the Scandinavian Simavastatin
Survival Study (4S) [21,22], the Cholesterol and Associ-
ated Events (CARE) study [7], or the Long-term Intervention
with Pravastatin in Ischemic Disease (LIPID) study [23],
which together show that the strongest intervention to
reduce the risk of heart attacks in diabetics may not be an
improved glucose control or a more aggressive lowering of
blood pressure, but rather a LDL reduction of 28–38%. The
advantage of LDL lowering applies to the most common
high risk phenotypes, because one of the most striking
results of the major statin trials is the larger clinical benefits
observed in individuals who have other risk factors in addi-
tion to the hypercholesterolemia (ie pre-existing CHD,
smoking, hypertension, diabetes, or family history of CHD).
Statins may, in this line of thinking, be seen as anti-athero-
genic agents that will impact on the overall CHD risk even
when the LDL component of the risk profile is not the most
prominent problem in the patient.Current Controlled Trials in Cardiovascular Medicine    Vol 2 No 1 Fazio and Linton
LDL goals in high risk patients
This information brings us to the central point of our argu-
ment; that is, the most important objective in LDL lowering
for high risk patients is the percentage change from base-
line rather than the reaching of any predefined on-treat-
ment goal. This view is corroborated by a large amount of
clinical trial data showing, first, that on-treatment LDL
levels do not predict CHD rates whereas baseline LDL
levels do [24]. Second, the correlation between LDL
reduction and CHD risk reduction within each study is at
best curvilinear even in high risk, high cholesterol popula-
tions where the average on-treatment LDL is still signifi-
cantly distant from the NCEP goal of 100 mg/dl [10].
Finally, the same percentage LDL reduction appears to be
more effective in subjects with higher baseline LDL (and
whose on-treatment LDL stays higher than 100 mg/dl)
compared with those with a lower baseline LDL (and
whose on-treatment LDL adjusts below 100 mg/dl)
[7,21,25]. With regard to the last point, Cullen and
Assmann propose the scenario in which higher doses of
statins would be needed in high risk patients with ‘average
cholesterol’ rather than in average risk patients with high
cholesterol [26]. Since statin treatment produces the
same relative reduction in cholesterol levels irrespective of
baseline concentrations, it follows that to accomplish the
same absolute reduction in cholesterol (eg 40 mg/dl),
more aggressive intervention must be given to produce a
cholesterol decrease from 200 to 160 mg/dl (20% reduc-
tion) than to decrease it from 260 to 220 mg/dl (15%
reduction). It is interesting to note that when the correla-
tion between LDL reduction and coronary events is ana-
lyzed on a large scale, including statin and non-statin trials,
less additional clinical benefits are expected from choles-
terol reductions larger than 15%, indicating that this rela-
tionship is governed by a law of diminishing returns
[15,27]. Considering that each doubling of statin dose
reduces LDL only by an additional 6–7% [28,29], the
cost-effectiveness of high dose statin treatment in the
long-term care of patients with common hypercholes-
terolemia remains to be evaluated. On the contrary, it is
clear that high risk patients with high cholesterol (eg sub-
jects with familial hypercholesterolemia) should be treated
with the most aggressive regimens available and that they
represent the best targets for the new ‘superstatins’ now
in the experimental phase, which can reportedly reduce
LDL cholesterol approximately 65–70% [30].
To state it simply, the proponents of aggressively low LDL
goals would like to see every high risk patient reach a LDL
level of 70–90 mg/dl. This position is flawed for the follow-
ing reasons. First, many high risk patients with severe
hypercholesterolemia (LDL level >200 mg/dl) will not be
able to reach that goal even at the highest doses of more
than one lipid-lowering agent. Setting unreasonable,
nonevidence-based goals will affect patient compliance,
the ultimate objective to make an impact on CHD risk.
Second, the cyclical variations in LDL induce oscillations
whose range often encompasses a predefined goal in
high risk patients with moderate hypercholesterolemia,
thus triggering unjustified dose adjustments or changes of
drug. Finally, the high risk patients without hypercholes-
terolemia (LDL level <100 mg/dl) may be denied LDL low-
ering intervention because they are already ‘at goal’. Our
position is also simple, but has the additional advantages
of being feasible throughout the range of cholesterol dis-
tributions and being completely based on published clini-
cal evidence. We support the concept that the most
effective LDL intervention in high risk patients is to achieve
a reduction of at least 30%. This concept is based on the
knowledge that atherosclerosis initiation and progression
depend on plasma cholesterol, and that the vast majority
of LDL concentrations in western populations are suffi-
cient to support plaque formation in the appropriate ‘per-
missive’ environment. Our strategy complies with the
NCEP guidelines, as most of the high risk patients treated
with an average dose of an average statin would experi-
ence a 30–40% LDL reduction that would put on-treat-
ment LDL levels safely below goal. Our position differs
from both the guidelines and the proponents of more
aggressive LDL goals in the management of the two
extremes of the cholesterol distribution, where our lack of
interest in a predefined on-treatment LDL concentration
would make us more aggressive than guidelines on low
baseline LDL patients and less aggressive than guidelines
on high baseline LDL patients.
Conclusions
If, at the end of this discussion, the two positions seem to
have more similarities than differences, it is because they
do. The controversy on which to set LDL goals in high risk
patients is actually not a burning social or clinical issue, as
little disagreement exists on the value of LDL lowering in
high risk patients, and therapy is commonly limited to the
use of one statin or another. Different statins at different
doses provide, overall, a narrow range of LDL reductions
accompanied with significant variation in individual
responses, so that different philosophical viewpoints are
not easily translated into different practical stances.
The greatest difference between the two viewpoints is in
the use of cholesterol lowering as a means to reduce car-
diovascular disease in the population. The proponents of
aggressive LDL lowering intend to eradicate atherosclero-
sis by acting on its initiating factor, with the assumption
that adequately low LDL levels will impede lesion growth
in most individuals, irrespective of their underlying risk
profile. We consider cholesterol lowering as one of the
many battles in the war on atherosclerotic disease, a war
that will not be won without a concerted attack against the
other major players in the enemy camp, including inactive
lifestyle, the western diet, obesity, cigarette smoking, dia-
betes, and hypertension.Available online http://cvm.controlled-trials.com/content/2/1/008
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